← Back to Search

TAS-120 (futibatinib) monotherapy for Cancer

Phase 2 & 3
Waitlist Available
Research Sponsored by Taiho Oncology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 5 years
Awards & highlights

Summary

This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with serious adverse events, treatment-related adverse events, and any AEs leading to treatment discontinuation graded according to NCI-CTCAE v5.0.

Trial Design

2Treatment groups
Experimental Treatment
Group I: TAS-120 (futibatinib) monotherapyExperimental Treatment1 Intervention
TAS-120 tablets, oral, cycle length is defined as per antecedent study design
Group II: TAS-120 (futibatinib) combination therapy with fulvestrantExperimental Treatment1 Intervention
TAS-120 tablets in combination with fulvestrant, oral, cycle length is defined as per antecedent study design

Find a Location

Who is running the clinical trial?

Taiho Oncology, Inc.Lead Sponsor
70 Previous Clinical Trials
11,682 Total Patients Enrolled
~10 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top